Physician profile
Cassandra Baier
NPI 1396289674
$6,610.32
in general payments reported to CMS, 2019-2025
26 companies · $1,773 in 2025
The $1,773 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,450 · 2022: $507 · 2023: $1,416 · 2024: $1,464 · 2025: $1,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,249 · Education: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,249.21 |
| Education | $403.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,209.05 | 2021-2025 | |
| Abbvie INC. | $1,117.40 | 2021-2025 | |
| Janssen Biotech, INC. | $980.28 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $792.69 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $427.68 | 2021-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $276.15 | 2021-2025 | Ilumya |
| Ucb, INC. | $221.45 | 2021-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $208.79 | 2021-2025 | |
| Leo Pharma INC. | $191.85 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $176.50 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $170.63 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $132.45 | 2021-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $118.30 | 2021-2025 | Cabtreo |
| Amgen INC. | $112.45 | 2022-2024 | Otezla |
| Sanofi-Aventis U.S. LLC | $99.00 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $78.09 | 2021-2025 | Opzelura |
| Organon LLC | $55.66 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.28 | 2023-2024 | Spevigo |
| Epi Health, LLC | $42.64 | 2022 | |
| Verrica Pharmaceuticals INC. | $33.27 | 2025 | Ycanth |
| Organogenesis INC. | $29.32 | 2022 | |
| Botanix Sb INC | $23.13 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $17.84 | 2024 | Zoryve |
| Biofrontera INC. | $16.58 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $15.25 | 2023 | Valchlor |
| Journey Medical Corporation | $13.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Baier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.